Cara Therapeutics (NASDAQ:CARA) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a report published on Monday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Stock Performance

Cara Therapeutics stock opened at $0.29 on Monday. Cara Therapeutics has a fifty-two week low of $0.24 and a fifty-two week high of $1.40. The firm’s fifty day moving average price is $0.29 and its 200-day moving average price is $0.43. The stock has a market cap of $15.80 million, a P/E ratio of -0.12 and a beta of 0.70.

Cara Therapeutics (NASDAQ:CARA) last issued its quarterly earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.10). The firm had revenue of $0.99 million for the quarter, compared to the consensus estimate of $1.26 million. Cara Therapeutics had a negative return on equity of 241.31% and a negative net margin of 1,010.20%. On average, analysts predict that Cara Therapeutics will post -1.24 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cara Therapeutics stock. Marquette Asset Management LLC bought a new stake in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 94,238 shares of the biopharmaceutical company’s stock, valued at approximately $86,000. Marquette Asset Management LLC owned about 0.17% of Cara Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 44.66% of the company’s stock.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.